Navigation Links
Craig Johnson Joins Ardea Biosciences' Board of Directors
Date:6/12/2008

e 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our A
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
2. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
3. Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life
4. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
5. Johnson & Johnson Announces Changes to Accelerate Growth
6. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
7. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
8. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
9. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
10. Loic Maurel Joins Exonhit Therapeutics to Become CEO
11. David M. Stout Joins NanoBio Corporations Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 27, 2015 Research ... the "Animal Genetics Market by Products, by Testing ... their offering. The global animal genetics market ... 2014 and grow at a CAGR of 8-9% during ... This market is mainly driven by increasing animal protein ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 28, 2015  PDS Biotechnology Corp. announces preliminary ... targeting HPV-16, has generated strong T-cell responses in ... cancer is treated by surgical removal of lesions ... non-surgical alternative. Results show that it primes and ... target, and kill precancerous and cancerous cells that ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... cooperative research center program (I/UCRC) will "provide a one-stop ... wide range of metamaterials." Dr. David Crouse, associate ... Engineering at The City College of New York, serves ... Participating institutions are The City University of ...
... Inc. (OTCBB: PEDX) announced that the U.S. Centers ... state Medicaid agencies to include PediatRx,s GRANISOL, NDC ... funds the Medicaid and State Children Health Insurance ... health insurance, including prescription drug coverage, to over ...
... 2011 Cellular Dynamics International (CDI), the ... induced pluripotent stem cell (iPSC) lines, today announced it ... patented definitive endoderm differentiation technology from ViaCyte, Inc. ... CDI will apply this patented methodology in the development ...
Cached Biology Technology:Grove School professor leads new metamaterials center 2Grove School professor leads new metamaterials center 3Grove School professor leads new metamaterials center 4GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 2GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 3GRANISOL™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement 4Cellular Dynamics Licenses Technology From ViaCyte 2Cellular Dynamics Licenses Technology From ViaCyte 3
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... in the Proceedings of the National Academy of Sciences ... from the Kennedy Krieger Institute and four collaborating institutions, identified ... to the development of glaucoma and its resulting vision loss. ... head, the point where the cables that carry information from ...
... researchers led by Daniel J. Rader, MD, associate ... and Therapeutics, has received a $6 million grant ... molecular genetics of atherosclerotic cardiovascular disease. The team,s ... Plasma Lipids and Cardiovascular Disease," was selected to ...
... vomiting hairballs or refusing to eat probably isn,t being finicky ... is a good chance that the cat is acting sick ... new research suggests. Healthy cats were just as likely ... leave waste outside their litter box in response to changes ...
Cached Biology News:New research reveals unexpected biological pathway in glaucoma 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Even healthy cats act sick when their routine is disrupted 2Even healthy cats act sick when their routine is disrupted 3Even healthy cats act sick when their routine is disrupted 4Even healthy cats act sick when their routine is disrupted 5
Request Info...
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
... top-of-the-line PowerPac 3000 power supply is ... ideal for isoelectric focusing, DNA sequencing, ... electrophoresis, western blotting, and submerged gel ... of powre, the PowerPac 3000 power ...
... GT cell and PowerPac basic power supply are ... acids in agarose gels. The wide mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
Biology Products: